Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) ...

Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following ...

A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website. For more information about this conference ...

Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General ...

A live webcast and replay of the presentation will be available in the "Upcoming Events” and "News” sections of Pharming's website. For more information about this conference, or to schedule a ...

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...

Staying aware of cyberattacks and how to recognize and prevent them can significantly reduce the impact of the human element ...

Pharming Group (NASDAQ:PHAR) has nominated Fabrice Chouraqui as its new Executive Director and CEO, succeeding Sijmen de Vries.The appointment will be for a four-year term, subject to shareholder ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...